Regulation of cGMP-induced relaxation and cGMP-dependent protein kinase in rat myometrium during pregnancy

R. Ann Word1 and Trudy L. Cornwell2

1 Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75235-9032; and 2 Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Increases in guanosine 3',5'-cyclic monophosphate (cGMP) induced by nitric oxide (NO), nitrovasodilators, and atrial peptides correlate with relaxation of vascular smooth muscle. Relaxation of myometrial smooth muscle by increases in cGMP, however, has required unusually high concentrations of the cyclic nucleotide. We tested the hypothesis that the sensitivity of myometrium to relaxation by cGMP is increased during pregnancy. Aortic smooth muscle was more sensitive to relaxation by cGMP than myometrial tissues, and, contrary to our hypothesis, myometrium from pregnant rats was least sensitive. Although levels of cGMP were elevated after treatment with the NO donor, S-nitroso-N-acetylpenicillamine, relaxation of myometrial tissues obtained from pregnant rats occurred only at extraordinarily high concentrations. The levels of cGMP-dependent protein kinase (PKG) were significantly decreased in myometrium from pregnant rats compared with myometrium from nonpregnant cycling animals or aortic smooth muscle. Administration of estradiol to ovariectomized rats increased myometrial PKG expression, and progesterone antagonized this response. We conclude that 1) myometrial tissues from pregnant rats are not sensitive to relaxation by cGMP and 2) this insensitivity to cGMP is accompanied by progesterone-mediated decreases in the level of PKG expression.

nitric oxide; progesterone; guanosine 3',5'-cyclic monophosphate phosphodiesterase; oxytocin; atrial natriuretic peptide

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

THE BIOCHEMICAL PROCESSES that initiate labor in women are not known. In addition, the precise mechanisms that serve to maintain uterine quiescence during pregnancy are not well understood. Because the incidence of preterm labor has remained constant for decades, and preterm labor remains a major cause of perinatal mortality and infant morbidity, modulators of myometrial function during pregnancy have been eagerly sought. Recently, it has been proposed that nitric oxide (NO) may be an endogenous uterine relaxant that contributes to uterine quiescence during pregnancy before term (18, 31). In addition, it has been suggested that relief of NO action may lead to retreat from uterine quiescence with the onset of spontaneous uterine contractions of labor (24).

In general, the smooth muscle relaxant effects of NO, atrial peptides, and drugs that liberate NO are mediated by guanosine 3',5'-cyclic monophosphate (cGMP). The downstream target for cGMP is believed to be the cGMP-dependent protein kinase (PKG), which mediates the vasorelaxant effects of cGMP (5, 10, 15). Whereas increases in cGMP correlate with relaxation in a time- and concentration-dependent manner in vascular smooth muscle (15), the role of cGMP as a uterine relaxant is not as well established. For example, there is no correlation between increases in cGMP and relaxation in myometrial smooth muscle (7), and increases in cGMP that effect almost complete relaxation of tonic smooth muscles have relatively little effect in uterine smooth muscle (7, 29). To resolve this apparent conundrum, several laboratories have investigated the possibility that uterine smooth muscle responds to cGMP-mobilizing agents as a function of the hormonal milieu. Bek et al. (3) reported that estradiol-primed rat myometrium relaxed in response to atrial natriuretic peptide (ANP). Potvin and Varma (22) found that myometrium from pregnant or progesterone-treated rats was refractory to ANP (21, 23). In other studies, however, it has been suggested that responses to cGMP-mobilizing agents may be enhanced during pregnancy (31). Thus, although experimental evidence supports a hormone dependence to the relaxant properties of cGMP, it remains uncertain whether pregnancy enhances or diminishes cGMP action in uterine smooth muscle.

In this investigation, we compared the effects of NO donors and cGMP on contractile properties of aortic smooth muscle and on myometrial smooth muscle from nonpregnant and pregnant rats. We initially reasoned that, during pregnancy, myometrial sensitivity to cGMP may be similar to that of vascular smooth muscle, thereby providing a potential mechanism of uterine quiescence. The results of these studies, however, indicate that myometrial tissues obtained from pregnant rats are insensitive to relaxation by cGMP. Furthermore, the levels of PKG in uterine smooth muscle are significantly decreased during pregnancy, and this downregulation of PKG during pregnancy is mediated by progesterone. These latter findings provide a mechanism, at least in part, for the diminished sensitivity of uterine smooth muscle to cGMP during pregnancy.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Source of smooth muscle tissues. Ovariectomized and late pregnant (days 17-21) Sprague-Dawley rats (180-250 g) were obtained from Sasco Laboratories. Daily subcutaneous injection of hormones was initiated at 3-wk postovariectomy and continued for a total of 3 days: 50 µg/kg 17beta -estradiol, 2 mg/kg progesterone, 17beta -estradiol plus progesterone or vehicle (corn oil, 200 µl). Rats were killed the day after completion of hormone treatment, and uteri were dissected. For the late pregnant group, gestational dating was performed by vaginal smears. The first day of pregnancy was estimated by estrus pattern with sperm present. All studies were conducted in accordance with the standards of humane animal care as described in the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Review Board for Animal Research. Uterine and aortic tissues were placed in ice-cold physiological saline solution (PSS; in mM: 120.5 NaCl, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 20.4 NaHCO3, 2.5 CaCl2, 10.0 D-glucose, and 1.0 pyruvate) and gassed with 95% O2 and 5% CO2. The tissues were then prepared immediately for experimental studies.

Evaluation of smooth muscle contractile properties. Each uterine horn was opened longitudinally along the mesenteric border. The endometrium was removed with a cotton-tip applicator and by sharp dissection using a dissecting microscope. Aortic tissues were removed, cleaned of adjacent tissues, and opened longitudinally. Myometrial strips (1 × 3 × 0.5 mm) were cut parallel to the longitudinal muscle fibers, and aortic strips (0.5 × 1 × 0.2 mm) were cut transversely. Myometrial strips were hung from Grass FT 0.036 transducers using 6-0 braided silk suture, and aortic strips were mounted with vascular clamps. Clamps or sutures were attached to steel rods mounted on calibrated mechanical drives. Tissues were incubated in PSS (37°C), and contractions were recorded on a Grass model 7 polygraph. Optimal length for maximal force development (Lo) was determined by length-force relationships. Strips at Lo were conditioned by one contraction in PSS that contained KCl (65 mM) substituted isotonically for NaCl. Aortic smooth muscle strips were conditioned by two phenylephrine (0.1 µM)-induced contractions. In myometrial tissues, active force was quantified by digitizing the physiograph tracing of isometric force developed during 10 min and computing the area of active force (30). In each strip, the area of active force after treatment with test agents was compared with changes in force development at the corresponding time intervals in separate control aortic and myometrial strips.

Radioimmunoassay of cGMP. Muscle strips were mounted for quantification of force generation (described above) and treated with vehicle or test agents for 5 min. Tissues were snap frozen with tongs precooled to the temperature of liquid nitrogen and immediately homogenized in ice-cold extract buffer that contained HCl (0.1 N) and methanol (50%, vol/vol). Samples were centrifuged at 10,000 g for 10 min, and supernatants were lyophilized, acetylated, and assayed for cyclic nucleotide content by radioimmunoassay as described (12). Precipitated protein was determined using the bichinchoninic acid protein assay (Pierce, Rockford, IL).

Immunoblot analysis of PKG. Proteins in tissue extracts were separated by electrophoresis on sodium dodecyl sulfate (SDS)-polyacrylamide gels (7%). Proteins were transferred to nitrocellulose at 90 mA for 14-16 h in the presence of methanol (20%) and SDS (0.1%). Blots were treated with TBST-milk buffer [10 mM tris(hydroxymethyl)aminomethane, 150 mM NaCl, 0.05% Tween 20, and 0.3% powdered milk] for 1 h and then incubated overnight with TBST-milk that contained a polyclonal antibody against bovine lung PKG (1:1,000) at 4°C. Thereafter, the blots were washed three times with TBST (5 min each) and incubated with goat anti-rabbit immunoglobulin G conjugated with horseradish peroxidase (1:10,000). After an extensive washing with TBST, the blots were developed with a chemiluminescent detection system (enhanced chemiluminescence Western blotting detection system). Relative amounts of PKG were quantified using an LKB 2202 Ultroscan laser densitometer. Quantification was obtained from blots in which densitometric units were linear with respect to amounts of purified PKG standards and protein loaded on the gel.

Assay for PKG. PKG activity was determined from crude soluble extracts. Incorporation of 32P from [gamma -32P]ATP into histone F2b was monitored using a filter paper assay (16).

Materials. S-nitroso-N-acetyl-penicillamine (SNAP) was purchased from Research Biochemicals International (Natick, MA). The monophosphorothioate activator of PKG, 8-(4-chlorophenylthio)guanosine 3',5'cyclic monophosphate (8-CPT-cGMP) was obtained from Biolog (La Jolla, CA). M2056 was obtained from LC Laboratories (Woburn, MA). Radiolabeled compounds ([gamma -32P]ATP and [125I]-labeled cGMP) were from DuPont NEN (Boston, MA), and the bichinchoninic acid protein assay reagents were from Pierce. The enhanced chemiluminescence Western blotting detection system was obtained from Amersham (Arlington Heights, IL). All other reagents were from Sigma (St. Louis, MO) or Fisher Biochemicals (Pittsburgh, PA).

Statistics. Data are expressed as means ± SE. For multiple comparisons, data were analyzed using a nonparametric Kruskal-Wallis analysis followed by chi 2 approximation. Differences between aorta and myometrium were determined with Mann-Whitney's U test for two independent variables.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Effect of activators of guanylate cyclases and cGMP phosphodiesterase inhibitors on smooth muscle contractility. To compare the effects of cGMP in vascular and uterine smooth muscles, we treated aortic and myometrial tissues from pregnant rats with sodium nitroprusside (SNP), a prototype of NO donors known to increase cellular levels of cGMP (Fig. 1). Strips were precontracted with submaximal concentrations of phenylephrine (0.1 µM) or oxytocin (1 nM) to effect similar degrees of agonist-induced contractions. Thereafter, the tissues were treated with cumulative concentrations of SNP (10-8 to 10-4 M). Treatment with SNP (0.1 µM) resulted in almost complete relaxation of precontracted aortic smooth muscle (98 ± 0.7%, n = 5, Fig. 1B) but virtually no detectable decreases in the frequency or amplitude of oxytocin-induced contractions in myometrial tissues (Figs. 1D and 2). This refractoriness to SNP in myometrial tissues was not unique to oxytocin. Myometrial tissues precontracted with 5-hydroxytryptamine were also insensitive to relaxation by SNP (data not shown). The effects of SNP on contractile force of both tissues are summarized in Fig. 2. Maximal relaxation of myometrial tissues (70%) was effected by 1 × 10-4 M and half-maximal effects at 3 × 10-5 M. Although high concentrations of SNP (>= 100 µM) abolished contractile activity in oxytocin-contracted myometrial tissues, these effects were irreversible and spontaneous activity did not resume after several rinses with PSS or after depolarization with KCl (40 mM). Thus, compared with aortic smooth muscle, SNP was less effective in relaxing myometrium from pregnant rats. Similar results were obtained with the NO donor SNAP (Fig. 2, right). The concentration of SNAP required to effect 50% inhibition of contractile force in aortic smooth muscle was significantly less than that required for myometrium (4.2 ± 0.2 × 10-8 M, aorta compared with 2.2 ± 0.4 × 10-4 M in myometrium, P < 0.01).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of sodium nitroprusside (SNP) on force of contraction in aortic and myometrial smooth muscle from pregnant rats. Representative tracings of SNP-induced relaxation of agonist-induced contractions in aorta (A and B) and myometrium (C and D) from pregnant rats (day 17). Both tissues were treated with submaximal concentrations of contractile agents. Aortic smooth muscle was treated with phenylephrine (PE; 0.1 µM), and myometrial tissues were treated with oxytocin (OX; 1 nM). Thereafter, the muscle was treated with vehicle (control strip, A and C) or varying concentrations of SNP (B and D). Treatment of myometrial tissues with high concentrations of SNP (0.1 mM) resulted in irreversible cessation of contractile activity.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of SNP and S-nitroso-N-acetylpenicillamine (SNAP) on force of contraction in aortic and myometrial (MYO) smooth muscle from pregnant rats. Cumulative dose-response curves were obtained for SNP (left) or SNAP (right) in aortic (bullet ) and myometrial (open circle ) tissues from pregnant rats. In myometrial tissues, extent of inhibition of contractile force in response to oxytocin was determined by computing the area under the curve of isometric force development after treatment with test agent. Relaxing effect of test agents was corrected for changes in force development observed at the corresponding time intervals in control strips. Data represent means ± SE of 4-9 strips from 8 rats.

The effect of SNP on spontaneous contractions in myometrium from nonpregnant and pregnant rats was also determined (Fig. 3). Although treatment with SNP resulted in very small decreases in the amplitude of force development in both tissues, the predominant effect of SNP was to decrease the frequency of spontaneous contractions (Fig. 3, top). Myometrium from nonpregnant animals in estrus was more sensitive to relaxation by SNP than that from pregnant animals (Fig. 3, bottom). A comparison of these data, along with those presented in Figs. 1 and 2, clearly indicates that myometrial tissues are less responsive to SNP than aortic smooth muscle, and myometrium from pregnant animals is even less sensitive than myometrium from nonpregnant animals. The apparent increased relaxation of oxytocin-induced contractions (70%, Fig. 2) compared with spontaneous contractions (10%, Fig. 3) is due to the irreversible abolishment of contractions in some oxytocin-contracted tissues treated with high concentrations of SNP.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of SNP on spontaneous contractions in myometrial tissues from nonpregnant and pregnant rats. Top: effect of SNP (1 mM) on frequency and amplitude of spontaneous contractions in myometrium from nonpregnant (solid bar) and pregnant (open bar) rats. Bottom: dose-dependent inhibition of spontaneous contractions in myometrium from nonpregnant (bullet ) and pregnant (open circle ) rats. Extent of inhibition represents the decline in area of isometric force development during spontaneous contractions 20 min before and after treatment with SNP. Data represent means ± SE of 3-9 strips for 2 pregnant (day 17) rats and 3 nonpregnant rats in estrus. Apparent single points represent data where SE is very low.

An alternative mechanism known to elevate cGMP levels was also tested. Natriuretic peptides elevate cGMP by binding to extracellular receptors that are transmembrane guanylate cyclases. Stimulation of particulate guanylate cyclase by ANP (0.1 µM) resulted in significant relaxation (85%) in phenylephrine-induced contractions in aorta (Fig. 4). Precontracted myometrial tissues from pregnant rats, however, were insensitive to relaxation by ANP (Fig. 4). Thus myometrium from pregnant rats was not sensitive to activators of either particulate or soluble guanylate cyclases. Insensitivity to agents that synthesize cGMP may be due to increased cellular levels of cGMP phosphodiesterase activity. To test this hypothesis, we treated myometrial and aortic smooth muscles with a selective inhibitor of cGMP phosphodiesterase (M2056, 10 µM). Inhibition of cGMP phosphodiesterase resulted in 47 ± 10% relaxation of aortic smooth muscle within 10 min (n = 3, Fig. 5A). The same concentration of M2056 had no effect on oxytocin-induced myometrial contractions (Fig. 5B). In addition, preincubation of myometrial tissues with M2056 for up to 20 min did not alter the relaxation response to SNAP (10-6 M).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of atrial natriuretic peptide (ANP) on contractions in aortic and uterine smooth muscle from pregnant rats. Representative tracings of ANP-induced relaxation of precontracted aortic (A) and myometrial (B) tissues from pregnant rats (day 17). Arrows indicate the addition of ANP (0.1 µM). Tracings are representative of 4 separate experiments with similar results.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of M2056 on force of contraction in smooth muscle obtained from the aorta and myometrium of pregnant rats. Aortic (A) and myometrial (B) tissues were precontracted with phenylephrine (0.1 µM) and oxytocin (1 nM), respectively. Thereafter, tissues were treated with a guanosine 3',5'-cyclic monophosphate (cGMP) phosphodiesterase inhibitor (M2056, 10 µM).

cGMP production in myometrial and aortic tissues. Production of cGMP may be impaired in myometrial tissues, thereby providing an explanation for the apparent refractoriness of this tissue to activators of guanylate cyclases. To ensure that cellular levels of cGMP were increased in myometrial tissues by NO donors and cGMP phosphodiesterase inhibitors, myometrial and aortic tissues were treated with SNAP (1 µM), ANP (0.1 µM), M2056 (10 µM), or SNAP + M2056 for 5 min and homogenized, and the tissue content of cGMP was determined by radioimmunoassay. In both aortic and myometrial tissues, levels of cGMP increased significantly after treatment with SNAP, M2056, or SNAP + M2056 (Table 1). In contrast, ANP resulted in increased tissue levels of cGMP in aortic but not myometrial tissues from pregnant animals (P = 0.06).

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Tissue content of cGMP in aortic and myometrial tissues

Effect of cGMP analogs on smooth muscle contractility. We utilized two poorly hydrolyzed analogs of cGMP to assess the sensitivity of vascular and myometrial smooth muscles to cGMP, thereby circumventing any requirement for tissue guanylate cyclases and avoiding the metabolism of cGMP by tissue phosphodiesterases. We quantified the effects of 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) on oxytocin-induced contractions in myometrium and aorta (Fig. 6). Precontracted aortic (Fig. 6A) and myometrial (Fig. 6B) smooth muscle strips were treated with increasing concentrations of 8-BrcGMP (10-6 to 10-4 M), and the decrease in force generation was quantified over time. Whereas 8-BrcGMP (10-4 M) resulted in significant inhibition of phenylephrine-induced contractions in aortic smooth muscle (86 ± 2.7%, n = 5), precontracted myometrial tissues from pregnant rats responded to 8-BrcGMP (10-4 M) with only small decreases in both amplitude (17 ± 6%) and frequency (7 ± 6%) of contraction. Similar results were obtained with 8-CPT-cGMP, an analog of cGMP that is more resistant to cGMP hydrolysis than 8-BrcGMP (10). Myometrial tissues from nonpregnant rats in estrus, however, were relaxed with 8-BrcGMP, thereby demonstrating a sensitivity similar to aortic smooth muscle (Fig. 7). Although myometrial tissues from nonpregnant rats in estrus were relaxed by 10-5 M 8-BrcGMP (Fig. 7A), myometrial tissues from rats in diestrus or from rats treated with progesterone were like those of pregnant rats and insensitive to 8-BrcGMP (Fig. 7B). Even high concentrations of 8-BrcGMP (10-4 M) were not effective in relaxing progesterone-dominated myometrium.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) on force of contraction in aortic and myometrial smooth muscle. A and B: representative tracings of the effect of 8-BrcGMP on contractions in aortic (A) and myometrial (B) tissues from pregnant rats (day 17). 8-BrcGMP was more effective in relaxing contractions of aortic smooth muscle. C: concentration-response curves to 8-BrcGMP in aortic (bullet ) and in myometrial tissues from pregnant rats (open circle ) and from nonpregnant rats in estrus (black-triangle). Myometrium from pregnant rats was less responsive to the effects of 8-BrcGMP than aorta or myometrium from nonpregnant animals in estrus. Data represent inhibition of the area of isometric force developed during 10 min as described in MATERIALS AND METHODS.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of 8-BrcGMP on spontaneous contractions in myometrial tissues from nonpregnant rats. Representative tracings of spontaneous contractions in myometrial tissues from nonpregnant, cycling rats in estrus (A) and nonpregnant rats treated with progesterone (B). Downward arrow reflects change of bathing medium with physiological saline solution. Upward arrows indicate addition of the indicated concentrations of 8-BrcGMP.

Levels of PKG in aortic and myometrial smooth muscles. We next examined the expression of the major receptor protein for cGMP, PKG, in myometrial and aortic tissues. Because myometrial smooth muscle from pregnant rats was relatively insensitive to relaxation by cGMP, we analyzed myometrial extracts from nonpregnant, pregnant, and postpartum rats for PKG by Western blot analysis (Fig. 8). Utilizing a polyclonal antibody to PKG, we found a single immunoreactive species of 78 kDa in all tissues examined. Myometrial extracts prepared from nonpregnant cycling rats contained the highest level of PKG, whereas enzyme levels were significantly reduced in extracts prepared from term myometrium (Fig. 8). Compared with nonpregnant myometrium, levels of PKG were three- to fivefold lower in myometrium obtained from pregnant animals at all gestational days tested (days 12, 15, 17, 18, and 20). Levels of PKG increased in the postpartum period and by the third postpartum day were similar to levels observed in nonpregnant animals (Fig. 8). PKG levels were similar in uterine horns from unilateral pregnant rats, indicating that regulation of PKG expression may be due to the hormonal milieu rather than mechanical factors induced by fetal occupancy (data not shown).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 8.   Levels of cGMP-dependent protein kinase (PKG) in nonpregnant, pregnant, and postpartum rat myometrium. Relative amounts of PKG were determined by Western blot analysis of extracts prepared from myometrium from nonpregnant, pregnant, and postpartum rats (10 µg/lane). Lane 1, nonpregnant rat in estrus; lane 2, pregnant animal at term (day 20); lane 3, postpartum day 1; lane 4, postpartum day 2; lane 5, postpartum day 3. Molecular mass markers are indicated to left.

Next, we compared the levels of PKG in aorta and myometrium from nonpregnant animals during defined phases of the estrus cycle (Fig. 9). Levels of PKG were greatest in aortic tissues. Myometrial extracts prepared from nonpregnant animals in proestrus or estrus contained relatively lower levels of the enzyme, yet these levels were greater than those found during late pregnancy (35% of aorta). Myometrial tissues from animals in diestrus (high progesterone-to-estrogen ratio) contained lower levels of PKG than myometrium from animals in estrus, and progesterone treatment of nonpregnant animals resulted in further decreases in enzyme immunoreactivity (30% of aorta). These results suggested that PKG was regulated by ovarian hormones. To test this hypothesis, we determined the relative amounts of PKG in aorta or myometrium from pregnant rats and in myometrium from ovariectomized rats treated with vehicle, estradiol, progesterone, or estradiol and progesterone (Fig. 10). The average densities of the immunoreactive bands from Western blots utilizing extracts from four groups of animals are also presented in Fig. 10. The same aortic extract was included in all blots to serve as an internal control. Estradiol administration resulted in marked increases in PKG expression in myometrial tissues to levels similar to those of aortic tissues. Although progesterone treatment did not affect the low baseline levels of PKG in myometrium of ovariectomized animals, progesterone significantly inhibited the estradiol-induced increase in myometrial PKG expression. The levels of PKG in myometrium from pregnant animals were similar to those in myometrium from ovariectomized animals or animals treated with progesterone.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 9.   Immunoreactive PKG in aortic and myometrial homogenates. Western blot analysis of tissue proteins (25 µg/lane) from aorta (AO), myometrium from animals in proestrus (PRO), estrus (E), and diestrus (DI), and myometrium from a progesterone-treated animal (P) and during late pregnancy (day 20, Preg). Blot is representative of data obtained from 3 sets of animals. Molecular mass markers are indicated to left.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 10.   Regulation of PKG levels by ovarian hormones. Relative amounts of PKG were determined by Western blot analysis of extracts prepared from aorta or myometrium from pregnant (PREG) or ovariectomized rats treated with vehicle (CTL), estradiol (E2), progesterone (P), or estradiol + progesterone (E2+P). PKG bands from 4 blots (4 groups of animals) were quantified by densitometric scanning. Arbitrary units from densitometry were expressed as percent, with the level in aorta considered 100%. Inset: representative immunoblot from one set of animals (lane 1, aorta; lane 2, CTL; lane 3, E2; lane 4, P; lane 5, E2+P; lane 6, PREG).

Activity of PKG in myometrial extracts from nonpregnant and pregnant rats. PKG assays were conducted to determine whether the decrease in immunoreactive PKG in myometrium from pregnant animals correlated with a decrease in the levels of active enzyme. Rat myometrial extracts were prepared and assayed for cGMP-stimulated histone kinase activity. Myometrial extracts prepared from nonpregnant rats (n = 3) contained high levels of histone kinase activity, both in the absence or presence of cGMP (without cGMP, 225 ± 45 pmol · min-1 · mg-1; with cGMP, 827 ± 92 pmol · min-1 · mg-1). cGMP-induced PKG activities in extracts from pregnant rats (n = 3, days 12-20) were significantly lower (without cGMP, 62 ± 14 pmol · min-1 · mg-1; with cGMP, 137 ± 66 pmol · min-1 · mg-1, P < 0.05). The meaning of the decreased basal histone kinase activity is not known because many cellular kinases are capable of phosphorylating histone F2b. Decreased cGMP-induced activity in myometrium from pregnant rats, however, indicates decreased PKG enzymatic activity. Thus the decreased enzymatic activity in pregnant myometrium parallels the decrease in PKG immunoreactivity by immunoblot analysis.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

It is perhaps ironic that some of the earliest investigations with cGMP were conducted with uterine smooth muscle; however, more than 20 years later, we have a better understanding of the role of cGMP in vascular smooth muscle than in myometrial smooth muscle. In the vasculature, endothelial NO or atrial peptides signal smooth muscle relaxation by intracellular increases in cGMP and activation of PKG (5, 15). It is feasible that NO, produced from nerve plexi, decidua (18, 24), or other resident cells of the myometrium (e.g., macrophages) could diffuse to myometrial smooth muscle cells, activate soluble guanylate cyclase, and increase cellular levels of cGMP. Thus NO-induced cGMP elevation may effect uterine relaxation in a manner analogous to NO action in the vasculature. It has been suggested that activation of guanylate cyclase by NO may effect uterine quiescence during pregnancy (18, 24, 31). However, other roles of NO or cGMP are clearly possible.

The notion that uterine smooth muscle responses to cGMP are modified by the hormonal milieu has been explored by several laboratories. Bek et al. (3) initially reported that ANP induced relaxation of rat myometrium after estrogen treatment. Subsequently, Potvin and Varma (22) reported that, during pregnancy, the rat uterus was refractory to relaxation by ANP. The insensitivity to ANP was associated with a progesterone-mediated decrease in the synthesis of cGMP by ANP (21) perhaps due to a decrease in ANP receptors (23). We also found that ANP does not significantly increase cGMP levels in myometrium from pregnant rats. Stimulation of the soluble guanylate cyclase, however, resulted in significant increases in tissue levels of cGMP in both myometrium and aorta. However, myometrial tissues failed to relax in response to these elevated levels of cGMP. Rapid degradation of cGMP is not the sole cause of this uterine insensitivity because inhibition of cGMP phosphodiesterase activity resulted in relaxation of aortic, but not uterine, smooth muscle from pregnant rats. Furthermore, bypassing production of cGMP using cell-permeant, phosphodiesterase-resistant analogs of cGMP (8-BrcGMP and 8-CPT-cGMP) failed to induce uterine relaxation. These findings suggest that, although decreased synthesis of cGMP by ANP may contribute to ANP insensitivity in myometrial tissues during pregnancy, additional mechanisms must be involved to explain pregnancy-related insensitivity to intracellular cGMP.

In this investigation, we found that myometrium from estrogen-primed normal cycling rats was more sensitive to 8-BrcGMP than myometrium from pregnant animals throughout late gestation (days 17-21). These findings are in agreement with those of Izumi et al. (14) who also reported that high concentrations (>100 µM) of 8-BrcGMP were required to relax myometrium from pregnant, laboring animals. We did not observe the reported relaxation of uterine smooth muscle from pregnant animals (days 16 and 18) by low-nanomolar concentrations of 8-BrcGMP (13, 32). The effective concentrations of 8-BrcGMP known to relax smooth muscle are generally 1-100 µM (10). 8-BrcGMP in the low-nanomolar range is probably insufficient to bind to PKG (10), cGMP phosphodiesterases (25), or any cGMP-binding channel characterized thus far (9).

The effect of SNP on contraction of myometrium from pregnant animals has also been evaluated by several investigators (13, 22, 31). Although Potvin and Varma (22) reported no suppression of contractile activity in response to SNP, Izumi et al. (14) reported that SNP eliminated spontaneous contractility but did not relax KCl-induced contractions. In another report, SNP resulted in complete cessation of spontaneous uterine contractions in pregnant rats (31). In each instance, however, very high concentrations of SNP (>= 1 mM) were required to produce an effect. In comparison, aortic smooth muscle strips are maximally relaxed with concentrations 10,000-fold less than that required for myometrium (i.e., 0.1 µM). The effects of SNP in uterine tissue may be due to nonspecific or even toxic effects of the drug. In the current study, we found that SNP-induced "relaxation" was irreversible and spontaneous activity did not resume after removal of the drug from the bathing solution. Thus responses to high concentrations of SNP (>1 mM) are not likely to be mediated by cGMP.

The essential role of PKG in mediating smooth muscle relaxation has been established for vascular and bronchiolar smooth muscle (5, 10, 15). In the current study, the gestational insensitivity of uterine smooth muscle to cGMP was also correlated with decreased levels of immunoreactive PKG and lower levels of PKG enzyme activity compared with tissues that relaxed in response to increases in cGMP. Thus the sensitivity of smooth muscle to cGMP (aorta > nonpregnant myometrium > pregnant myometrium) parallels the levels of immunoreactive PKG and PKG enzyme activity. This is the first report of specific hormonal regulation of PKG expression in cells.

Very little is known about the mechanisms that regulate expression of PKG. The finding that myometrial PKG levels vary during pregnancy, the postpartum period, and the estrus cycle suggests that enzyme expression is regulated by ovarian hormones. Our studies in ovariectomized animals indicate that estradiol upregulates myometrial PKG and that this estradiol-induced increase in PKG expression is suppressed by progesterone. The low levels of estrogen and progesterone in the immediate postpartum period in the rat are consistent with low levels of PKG expression in postpartum animals (days 1 and 2) with restoration of PKG levels by postpartum day 3. The finding that the low levels of PKG in myometrium from ovariectomized animals were not downregulated further by progesterone is not surprising because progesterone receptor expression is regulated by estradiol. Estradiol has also been reported to increase the levels of cGMP in uterine tissues (27). Increased levels of cGMP in conjunction with elevated levels of PKG would ensure increased PKG activity in estrogen-primed uterine tissues.

The physiological relevance of this regulatory pathway is unknown. PKG may mediate thus far uncharacterized physiological responses in uterine smooth muscle. For example, it is possible that the massive uterine smooth muscle cell hypertrophy that accompanies pregnancy may involve downregulation of cGMP action. Antiproliferative properties have been assigned to cGMP based on studies in mesangial (11) and arterial (6) smooth muscle cells. Alternatively, cGMP, perhaps through PKG, may also play a role in remodeling of the extracellular matrix, as it does in other tissues (19, 26).

In addition to PKG, there are other proteins in reproductive tissues that are regulated in opposing directions by estrogen and progesterone. For example, oxytocin receptors, the major gap junction protein, connexin 43, and interstitial collagenase are upregulated by estradiol and downregulated by progesterone (28). In most species at term, progesterone withdrawal, together with increasing levels of estrogen, leads to increased expression of oxytocin receptors, gap junctions, and cervical collagenase, thereby providing effective contractions of labor and cervical ripening. It has also been suggested that the contractile phenotype of uterine smooth muscle is increased by estradiol treatment and decreased by progesterone (2). The concept that estrogen promotes a "contractile" state whereas progesterone gives rise to "quiescence" suggests that the tissue functions as one or the other of these physiological states, depending on the hormonal milieu. It implies that procontractile mechanisms are expressed and functioning under estrogen domination and prorelaxant mechanisms are acting under the influence of progesterone. We speculate that estradiol, through PKG expression, may serve to increase proteins of the contractile phenotype in uterine smooth muscle. A similar role for PKG has been described in vascular smooth muscle (4). Progesterone, through suppression of PKG expression, may decrease the contractile phenotype of the cell, whereas estrogen facilitates smooth muscle function, i.e., force generation and relaxation.

Previously, we reported that, compared with smooth muscle from bovine trachealis, myometrial tissues from nonpregnant women were relatively insensitive to relaxation by cGMP (29). In the current investigation, we expanded these studies to demonstrate that, during pregnancy, myometrium from pregnant rats is even less sensitive to relaxation by cGMP than is myometrium from nonpregnant animals. The lack of sensitivity to relaxation is correlated with decreased expression of PKG in myometrial tissues. These results are consistent with those reported in pregnant human uterine smooth muscle where neither L-arginine nor inhibitors of NO synthase result in any alterations of contractility (14a). These in vitro studies do not support a role for cGMP in the maintenance of uterine quiescence during pregnancy and are consistent with results obtained in vivo. In vivo, NO synthase inhibitors do not affect uterine contractility, and neither NO synthase inhibitors nor NO donors alter the timing of parturition (1, 8, 17). Together, these data provide evidence that the NO-cGMP-signaling pathway is reduced and unavailable to mediate uterine quiescence during pregnancy. Downregulation of PKG may result in phenotypic alterations of myometrial cells that facilitate other adaptations of uterine smooth muscle during pregnancy such as cellular hypertrophy and remodeling of the extracellular matrix.

    ACKNOWLEDGEMENTS

We acknowledge Elizabeth Arnold, Martha Hayes, Dr. Jie Li, and Sharon Cook for expert technical assistance and Drs. Jim Stull and Tom Lincoln for thoughtful discussions. We also thank Drs. Diana Tucker and Ayalla Barnea for providing rat tissues during the early phase of this study.

    FOOTNOTES

This investigation was supported by National Institute of Child Health and Human Development Grants HD-26164 and HD-11149 (R. A. Word) and HD-32622 (T. L. Cornwell).

Address for reprint requests: R. A. Word, Dept. of Obstetrics and Gynecology, Univ. of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9032.

Received 2 May 1997; accepted in final form 5 December 1997.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1.   Ahokas, R. A., B. M. Mercer, and B. M. Sibai. Enhanced endothelium-derived relaxing factor activity in pregnant, spontaneously hypertensive rats. Am. J. Obstet. Gynecol. 165: 801-807, 1991[Medline].

2.   Batra, S. Hormonal control of myometrial function. In: The Uterus, edited by T. Chard, and J. G. Grudzinskas. Melbourne, Australia: Cambridge University Press, 1994, p. 173-192.

3.   Bek, T., B. Ottesen, and J. Fahrenkrug. The effect of galanin, CGRP and ANP on spontaneous smooth muscle activity of rat uterus. Peptides 9: 497-500, 1988[Medline].

4.   Boerth, N. J., N. B. Dey, T. L. Cornwell, and T. M. Lincoln. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J. Vasc. Res. 34: 245-259, 1997[Medline].

5.   Cornwell, T. L., and T. M. Lincoln. Regulation of intracellular Ca2+ levels in cultured vascular smooth muscle cells. Reduction of Ca2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. J. Biol. Chem. 264: 1146-1155, 1989[Abstract/Free Full Text].

6.   Cornwell, T. L, G. A. Soff, A. E. Traynor, and T. M. Lincoln. Regulation of the expression of cyclic GMP-dependent protein kinase by cell density in vascular smooth muscle cells. J. Vasc. Res. 31: 330-337, 1994[Medline].

7.   Diamond, J. Lack of correlation between cyclic GMP elevation and relaxation of nonvascular smooth muscle by nitroglycerin, nitroprusside, hydroxylamine and sodium azide. J. Pharmacol. Exp. Ther. 225: 422-426, 1983[Abstract].

8.   Diket, A. L., M. R. Peirce, U. K. Munshi, C. A. Voelker, S. Eloby-Childress, S. S. Greenberg, X. J. Zhang, D. A. Clark, and M. J. S. Miller. Nitric oxide inhibition causes intrauterine growth retardation and hind-limb disruptions in rats. Am. J. Obstet. Gynecol. 171: 1243-1250, 1994[Medline].

9.   Finn, J. T., M. E. Grunwald, and K. W. Yau. Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Annu. Rev. Physiol. 58: 395-426, 1996[Medline].

10.   Francis, S. H., B. D. Noblett, B. W. Todd, J. N. Wells, and J. D. Corbin. Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol. Pharmacol. 34: 505-517, 1988.

11.   Garg, U. C., and A. Hassid. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am. J. Physiol. 257 (Renal Fluid Electrolyte Physiol. 26): F60-F66, 1989[Abstract/Free Full Text].

12.   Harper, J. F., and G. Brooker. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J. Cyclic Nucleotide Res. 1: 207-218, 1975[Medline].

13.   Izumi, H., and R. E. Garfield. Relaxant effects of nitric oxide and cyclic GMP on pregnant rat uterine longitudinal smooth muscle. Eur. J. Obstet. Gynecol. Reprod. Biol. 60: 171-180, 1995[Medline].

14.   Izumi, H., C. Yallampalli, and R. E. Garfield. Gestational changes in L-arginine-induced relaxation of pregnant rat and human myometrial smooth muscle. Am. J. Obstet. Gynecol. 169: 1327-1337, 1993[Medline].

14a.   Jones, G. D., and L. Poston. The role of endogenous nitric oxide synthesis in contractility of term or preterm human myometrium. Br. J. Obstet. Gynaecol. 104: 241-245, 1997[Medline].

15.   Lincoln, T. M. Cyclic GMP and mechanisms of vasodilation. Pharmacol. Ther. 41: 479-502, 1989[Medline].

16.   Lincoln, T. M., C. L. Hall, C. R. Park, and J. D. Corbin. Guanosine 3':5'-cyclic monophosphate binding proteins in rat tissues. Proc. Natl. Acad. Sci. USA 73: 2559-2563, 1976[Abstract].

17.   Molnar, M., and F. Hertelendy. Nomega -nitro-L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy-induced refractoriness to vasopressor agents. Am. J. Obstet. Gynecol. 166: 1560-1567, 1992[Medline].

18.   Natuzzi, E. S., P. C. Ursell, M. Harrison, C. Busher, and R. K. Reimer. Nitric oxide synthase activity in the pregnant uterus decreases at parturition. Biochem. Biophys. Res. Commun. 194: 1-8, 1993[Medline].

19.   Perr, H. A., M. F. Graham, R. F. Diegelmann, and R. W. Downs. Cyclic nucleotides regulate collagen production by human intestinal smooth muscle cells. Gastroenterology 96: 1521-1528, 1989[Medline].

21.   Potvin, W., S. Mulay, and D. R. Varma. Inhibition of the tocolytic activity of atrial natriuretic factor by progesterone and potentiation by progesterone receptor antagonist RU486 in rats. Br. J. Pharmacol. 104: 379-84, 1991[Abstract].

22.   Potvin, W., and D. R. Varma. Refractoriness of the gravid rat uterus to tocolytic and biochemical effects of atrial natriuretic peptide. Br. J. Pharmacol. 100: 341-347, 1990[Abstract].

23.   Potvin, W., and D. R. Varma. Down-regulation of myometrial atrial natriuretic factor receptors by progesterone and pregnancy and up-regulation by oestrogen in rats. J. Endocrinol. 131: 259-266, 1991[Abstract].

24.   Sladek, S. M., A. C. Regenstein, D. Lykins, and J. M. Roberts. Nitric oxide synthase activity in pregnant rabbit uterus decreases on the last day of pregnancy. Am. J. Obstet. Gynecol. 169: 1285-1291, 1993[Medline].

25.   Turko, I. V., T. L. Haik, L. M. McAllister-Lucas, F. Burns, S. H. Francis, and J. D. Corbin. Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding. J. Biol. Chem. 271: 22240-22244, 1996[Abstract/Free Full Text].

26.   Vargas, S. J., S. N. Holden, P. M. Fall, and L. G. Raisz. Effects of atrial natriuretic factor on cyclic nucleotides, bone resorption, collagen and deoxyribonucleic acid synthesis, and prostaglandin E2 production in fetal rat bone cultures. Endocrinology 125: 2527-2531, 1989[Abstract].

27.   Vesely, D. L., and D. E. Hill. Estrogens and progesterone increase fetal and maternal guanylate cyclase activity. Endocrinology 107: 2104-2109, 1980[Abstract].

28.  Word, R. A. Parturition. In: Textbook of Reproductive Medicine, edited by B. R. Carr and R. E. Blackwell. Norwalk, CT: Appleton and Lange. In press.

29.   Word, R. A., M. L. Casey, K. E. Kamm, and J. T. Stull. Effects of cGMP on [Ca2+]i, myosin light chain phosphorylation, and contraction in human myometrium. Am. J. Physiol. 260 (Cell Physiol. 29): C861-C867, 1991[Abstract/Free Full Text].

30.   Word, R. A., K. E. Kamm, and M. L. Casey. Contractile effects of prostaglandins, oxytocin, and endothelin-1 in human myometrium in vitro: refractoriness of myometrial tissue of pregnant women to prostaglandins E2 and F2alpha . J. Clin. Endocrinol. Metab. 75: 1027-1032, 1992[Abstract].

31.   Yallampalli, C., R. E. Garfield, and M. Byam-Smith. Nitric oxide inhibits uterine contractility during pregnancy but not during delivery. Endocrinology 133: 1899-1902, 1993[Abstract].

32.   Yallampalli, C., H. Izumi, M. Byam-Smith, and R. E. Garfield. An L-arginine-nitric oxide-cyclic guanosine monophosphate system exists in the uterus and inhibits contractility during pregnancy. Am. J. Obstet. Gynecol. 170: 175-185, 1994[Medline].


AJP Cell Physiol 274(3):C748-C756
0363-6143/98 $5.00 Copyright © 1998 the American Physiological Society